


PRELIMINARY AMENDMENT
U.S. Application No.: Not Yet Assigned

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A crystal for an oral solid medicament of an indoline compound represented by the formula:



which shows an X-ray powder diffraction pattern characterized by main peaks of $5.5^\circ \pm 0.2^\circ$, $6.1^\circ \pm 0.2^\circ$, $9.8^\circ \pm 0.2^\circ$, $11.1^\circ \pm 0.2^\circ$, $12.2^\circ \pm 0.2^\circ$, $16.4^\circ \pm 0.2^\circ$, $19.7^\circ \pm 0.2^\circ$ and $20.0^\circ \pm 0.2^\circ$ as 2θ .

2. (original): An oral solid medicament for dysuria treatment comprising as an active ingredient the crystal as claimed in claim 1.

3. (currently amended): A medicament as claimed in claim 2, which comprises as a further active ingredient at least one member selected from a group of an α_1 -adrenoceptor blocking agent except for the indoline compound represented by the formula:

COc1ccccc1OCCN[C@H](C)Cc2ccc3c(c2)nc4ccccc34C(=O)NCCCCO


4. (currently amended): A medicament as claimed in claim 2-~~or 3~~, wherein the dosage form is capsules or tablets.

6. (currently amended): A medicament as claimed in claim 5, wherein the light shielding capsules ~~is a capsule~~ are capsules containing titanium oxide.

8. (currently amended): A medicament for dysuria treatment which comprises combining a medicament as claimed in claim 2 with a medicament comprising as an active

PRELIMINARY AMENDMENT
U.S. Application No.: Not Yet Assigned

ingredient at least one member selected from a group of an α_1 -adrenoceptor blocking agent except for the indoline compound represented by the formula:



an anticholinergic agent, a 5α -reductase inhibitor, a sex hormone agent, an antianxiety agent, a cholinergic agent, a cholinesterase inhibitor, an antiinflammatory agent ~~and or~~ an antibacterial agent.

9. (currently amended): A medicament as claimed in ~~any one of claims 2 to 8~~ claim 2, wherein the dysuria is caused by dysuria associated with urethra organized obstruction, dysuria associated with a disorder of urination control nerves or dysuria associated with urethra functional obstruction.

10. (currently amended): A medicament as claimed in ~~any one of claims 2 to 8~~ claim 2, wherein the dysuria is caused by prostate hypertrophy, urethra stricture, urethra calculus, prostate cancer, neurogenic bladder or lower urinary tract disorders.

Please add the following new claims:

11. (new): A medicament as claimed in claim 3, wherein the dosage form is capsules or tablets.

PRELIMINARY AMENDMENT
U.S. Application No.: Not Yet Assigned

12. (new): A medicament as claimed in claim 11, wherein the capsules are filled in a light shielding capsule or the tablets are coated by a coating material with a light shielding effect.

13. (new): A medicament as claimed in claim 12, wherein the light shielding capsules are capsules containing titanium oxide.

14. (new): A medicament as claimed in claim 3, wherein the dysuria is caused by dysuria associated with urethra organized obstruction, dysuria associated with a disorder of urination control nerves or dysuria associated with urethra functional obstruction.

15. (new): A medicament as claimed in claim 8, wherein the dysuria is caused by dysuria associated with urethra organized obstruction, dysuria associated with a disorder of urination control nerves or dysuria associated with urethra functional obstruction.

16. (new): A medicament as claimed in claim 3, wherein the dysuria is caused by prostate hypertrophy, urethra stricture, urethra calculus, prostate cancer, neurogenic bladder or lower urinary tract disorders.

17. (new): A medicament as claimed in claim 8, wherein the dysuria is caused by prostate hypertrophy, urethra stricture, urethra calculus, prostate cancer, neurogenic bladder or lower urinary tract disorders.